BHVN NYSE
Biohaven Ltd.
1W: +29.5%
1M: +15.2%
3M: +13.8%
YTD: +41.0%
1Y: -7.9%
3Y: -44.1%
$15.29
+0.84 (+5.81%)
Pre-Market: $15.25 (-0.04, -0.26%)
Weekly Expected Move ±14.9%
$10
$12
$14
$16
$18
Credit Risk of going bust: higher than 78% of companies Debt: 11.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.33 (down 98%), Biohaven Ltd. would be worth roughly what it owes.
Total debt $297.0M against a stock market value of $2.31B.
Distance to default 2.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $134.4M (short-term plus half of long-term), stock volatility 96.9%; Altman Z'' -27.13. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.33 (down 98%), Biohaven Ltd. would be worth roughly what it owes.
Total debt $297.0M against a stock market value of $2.31B.
Distance to default 2.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $134.4M (short-term plus half of long-term), stock volatility 96.9%; Altman Z'' -27.13. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.60
Bullish
2 bullish
1 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (100)
Traders Purchase High Volume of Biohaven Call Options (NYSE:BHVN)
Biggest stock movers Thursday: TSLA, BABA, TTMI, PG, and more
Biohaven surges as FDA accepts resubmission for Vyglxia for spinocerebellar ataxia
Biohaven licenses IgG degrader portfolio to Japan’s Ono
Engineers Gate Manager LP Purchases Shares of 39,058 Biohaven Ltd. $BHVN
Biohaven (BHVN) discloses options tied to SVP's son - Stock Titan
Biohaven (BHVN) Could Be 82% Undervalued Following FDA Hold On Opakalim Trials - simplywall.st
Biohaven (BHVN) Could Be 82% Undervalued Following FDA Hold On Opakalim Trials - simplywall.st
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) - PR Newswire
What Does Biohaven (BHVN) FDA Hold Mean For Its Opakalim Program? - simplywall.st
Biohaven’s epilepsy drug hit with FDA clinical hold
Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN) - Seeking Alpha
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
Biohaven's Ratty Setback; How Xenon Benefits - Investor's Business Daily
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
BHVN Stock Slips As Kv7 Deal Seen As Stopgap Move - StocksToTrade
BHVN Stock Slips As SK Deal Seen As Buying Time - timothysykes.com
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold? - Stocktwits
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?
FDA places partial hold on Biohaven’s epilepsy drug
At a glance: stocks gapping down premarket
Biohaven (BHVN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says
Biohaven stock downgraded at RBC Capital Markets (BHVN:NYSE) - Seeking Alpha
Biohaven downgraded at RBC Capital Markets after SK Biopharma deal
Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target
Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target - Yahoo Finance
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet - Yahoo Finance
BlackRock Inc. Invests $196.57 Million in Biohaven Ltd. $BHVN
Why Biohaven Stock Was Rocking the Market This Week
Why Biohaven Stock Was Rocking the Market This Week
Slate Medicines Starts Migraine Treatment Study
SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program - The Globe and Mail
Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels - Seeking Alpha
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program - Yahoo Finance
Why Biohaven Ltd. (BHVN) Stock Is Up Today - Quiver Quantitative
Biohaven Secures $795 Million Licensing Deal with SK Biopharmaceuticals - Intellectia AI
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout
Biohaven BHVN Stock Pops As Analysts Hike Targets - StocksToTrade
Biohaven Stock Rallies As Analysts Hike Price Targets - timothysykes.com
Biohaven stock holds Buy rating at TD Cowen after SK deal - Investing.com
Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal
Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal
Biohaven stock surges 7% on SK Biopharmaceuticals deal - Investing.com
SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'
Biggest stock movers Wednesday: SYRE, INTU, BHVN and more - Seeking Alpha
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Stocktwits
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Yahoo Finance
Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal - Yahoo Finance
SK Biopharmaceuticals and Biohaven Sign $795 Million Collaboration Agreement - Intellectia AI
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Why Is BHVN Stock Falling Premarket? - Stocktwits
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Stocktwits
HC Wainwright Issues Negative Outlook for Biohaven Earnings
Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement? - simplywall.st
Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses - simplywall.st
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
Biohaven Ltd. (BHVN) Stock Analysis: Exploring The 57.73% Potential Upside For Investors - DirectorsTalk Interviews
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
BIOHAVEN ($BHVN) Releases Q2 2026 Earnings - Quiver Quantitative
Bank of New York Mellon Corp Increases Holdings in Biohaven Ltd. $BHVN
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Groq director and early investor joins Biohaven's board immediately - Stock Titan
Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of “Moderate Buy” from Analysts
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 53% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Lobbying Update: $120,000 of BIOHAVEN LTD. lobbying was just disclosed | BHVN Stock News - Quiver Quantitative
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy?
Biohaven Announces Scientific Leadership Transitions
Biohaven (BHVN) Completes Enrollment in RISE3 Trial
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts
Why Wall Street Is Growing More Cautious on Biohaven (BHVN)
Why Wall Street Is Growing More Cautious on Biohaven (BHVN) - Yahoo Finance
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Why Is BHVN Stock Falling Premarket?
BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials - Insider Monkey
Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials
5 Stocks Paying Off Big Time - Insider Monkey
Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials - Yahoo Finance
Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares - simplywall.st
Pfizer (PFE) CFO Dave Denton to Step Down Effective August 15
Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biohaven Ltd (BHVN) Institutional Confidence - TradingKey
Biohaven Ltd. (BHVN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations - Seeking Alpha
Pfizer CFO Dave Denton stepping down in August 2026
CCORF Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Pfizer Announces Chief Financial Officer Transition
Biohaven (BHVN) Insider Trading Activity 2026 - MarketBeat
Biohaven Ltd (BHVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey